[Challenges for psychotropics in the context of the SARS-Cov-2 pandemic]

Encephale. 2020 Jun;46(3S):S116-S118. doi: 10.1016/j.encep.2020.04.009. Epub 2020 Apr 23.
[Article in French]

Abstract
in English, French

French recommendations have been proposed for psychotropics use and possible adaptations during the SARS-CoV-2 epidemic. Between uncertainties linked to the lack of data and speculations about possible benefits of psychotropics against the coronavirus, we propose here elements allowing to base the pharmacotherapeutic decisions potentially useful in Covid+ patients with psychiatric disorders.

Des recommandations françaises ont été proposées sur l’emploi des psychotropes et les adaptations éventuelles pendant l’épidémie au SARS-CoV-2. Entre incertitudes liées au manque de données et spéculations sur le fait que certaines médications psychotropes pourraient présenter un éventuel bénéfice face au coronavirus, nous proposons ici des éléments permettant de fonder les décisions pharmaco-thérapeutiques potentiellement utiles chez les patients Covid+ souffrant de troubles psychiatriques.

Keywords: COVID-19; Psychotropes; Psychotropics; Recommandations; Recommendations; SARS-Cov-2.

Publication types

  • Review

MeSH terms

  • Anti-Anxiety Agents / adverse effects
  • Anti-Anxiety Agents / therapeutic use
  • Antiviral Agents / adverse effects
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus* / drug effects
  • COVID-19
  • COVID-19 Drug Treatment
  • Comorbidity
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / epidemiology
  • Drug Repositioning*
  • Dyspnea / chemically induced
  • Dyspnea / etiology
  • Humans
  • Hypnotics and Sedatives / adverse effects
  • Hypnotics and Sedatives / therapeutic use
  • Mental Disorders / drug therapy
  • Mental Disorders / epidemiology
  • Pandemics*
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / epidemiology
  • Psychotropic Drugs / adverse effects
  • Psychotropic Drugs / pharmacology
  • Psychotropic Drugs / therapeutic use*
  • Respiration / drug effects
  • Risk Assessment
  • SARS-CoV-2

Substances

  • Anti-Anxiety Agents
  • Antiviral Agents
  • Hypnotics and Sedatives
  • Psychotropic Drugs